NCT01577173View on ClinicalTrials.gov

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Head and Neck Cancer
Interventions
DRUG

MEHD7945A

1100 mg iv every 2 weeks

DRUG

cetuximab

400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly

Trial Locations (51)

1303

Sofia

2010

Darlinghurst

2298

Waratah

2500

Wollongong

2650

Edegem

3002

Melbourne

4029

Brisbane

4032

Debrecen

5000

Namur

5004

Szolnok

5037

Kurralta Park

5800

Pleven

7000

Rousse

9024

Győr

10011

New York

10043

Orbassano

10126

Turin

12200

Berlin

20133

Milan

20162

Milan

21204

Baltimore

28041

Madrid

28050

Madrid

29425

Charleston

33100

Udine

33176

Miami

37007

Salamanca

37909

Knoxville

42003

Paducah

45122

Essen

46010

Valencia

60637

Chicago

64507

Saint Joseph

69373

Lyon

80045

Aurora

92118

Clichy

94305

Stanford

94805

Villejuif

300239

Timișoara

400015

Cluj-Napoca

400058

Cluj-Napoca

500019

Brasov

02114

Boston

02215

Boston

27599-7295

Chapel Hill

53705-2275

Madison

08035

Barcelona

CV2 2DX

Coventry

G12 0YN

Glasgow

SW3 6JJ

London

SM2 5PT

Sutton

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY